Biotheryx, Inc.

At the San Antonio Breast Cancer Symposium, our SVP of Drug Development and Biology, Dr. Aparajita Hoskote Chourasia, PhD, along with our Acting CMO, Dr. Jeremy Barton, joined Dr. Amita Patnaik, MD, FRCPC of START San Antonio in presenting the Trial in Progress poster for our currently enrolling first-in-human Phase 1A clinical study of BTX-9341 in HR+/HER2- breast cancer. BTX-9341 is a first-in-class CDK4/6 bifunctional degrader that significantly inhibits the transcription of CDK2 and Cylin E. Additionally, Dr. Hannah Majeski presented BTX-9341 preclinical data, highlighting its potential as a therapy to treat HR+/HER2- breast cancer patients resistant to CDK4/6 inhibitor therapy. For both SABCS posters, please visit our website: https://lnkd.in/gar3U7Jv ; https://lnkd.in/gFaaitdA. #SABCS #breastcancer

October is Breast Cancer Awareness Month, and Biotheryx is proud to be a part of the fight against this disease. More than 300K people will be diagnosed with breast cancer this year. We are energized by the great advancements in both early detection methods and breast cancer therapies, including our oral CDK4/6 bifunctional degrader known as BTX-9341, currently in Phase 1 clinical studies. While new breast cancer therapies are making a big impact, we encourage monthly breast self-exams and regular mammograms as advised by your physician. According to the Amercian Cancer Society, when breast cancer is detected in its early, localized stage, the 5-year relative survival rate is 99%. 

Today we announced that the first patient has been dosed in our Phase 1 trial of BTX-9341. This trial investigates BTX-9341 as both monotherapy and in combination with fulvestrant for patients with advanced and/or metastatic HR+/HER2- #breastcancer who are resistant to CDK4/6 inhibitor therapies. BTX-9341 is a potent and highly selective catalytic degrader of CDK4/6, and it also robustly inhibits the transcription of Cyclin E and CDK2. For more details, please see our full announcement here: https://lnkd.in/gmjWebAT

Our SVP of Drug Development and Biology, Aparajita Hoskote Chourasia, PhD, recently presented on the characterization of BTX-9341, our lead asset for HR+/HER2- #breastcancer at #ASCO24. To review the poster, please visit our website: https://lnkd.in/gyx77kG3

Tomorrow at #ASCO24, our SVP of Drug Development and Biology, Aparajita Hoskote Chourasia, PhD, will present a poster on BTX-9341, our first-in-class, dual bifunctional degrader of CDK4/6.

Our CEO, Leah Fung, spoke with BiotechTV's Brian Orelli, PhD this week regarding our targeted protein degradation platform, PRODEGY, and CDK4/6 bifunctional degrader program, BTX-9341, which is entering into the clinic for patients with HR+/HER2- #breastcancer resistant to CDK4/6 inhibitor therapies. Watch the full video here: https://lnkd.in/eADeFu5v

We are delighted to announce the acceptance of our IND application for BTX-9341, a first-in-class, orally bioavailable bifunctional degrader of CDK4/6. BTX-9341 is expected to enter a Phase 1 clinical trial in the second half of 2024 for patients with HR+/HER2- #breastcancer resistant to CDK4/6 inhibitor therapies. Press release: https://lnkd.in/gRbWj_na